Tyrosine News and Research

RSS

Comorbidities relevant to CML TKI choice common

Comorbid conditions that could affect the choice of tyrosine kinase inhibitor are common in patients with chronic myeloid leukaemia, finds an analysis of a US claims database.

27 Nov 2015

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia.

27 Nov 2015

Rare variants linked with Parkinson’s disease

Researchers using exome sequencing in families with Parkinson’s disease have identified two genes that could be associated with the condition.

27 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Sorafenib, a tyrosine kinase inhibitor (TKI) targeting the receptors for vascular endothelial growth factor, platelet derived growth factor, and mast/stem cell growth factor, modestly increases progression-free survival (PFS), time to progression, and disease control rate in non-small cell lung cancer (NSCLC) patients who have relapsed or failed two or three previous treatment regimens.

10 Nov 2015

Hutchison MediPharma begins sulfatinib Phase I trial in US

Hutchison China MediTech Limited today announces that Hutchison MediPharma Limited ("HMP"), its drug R&D subsidiary, has initiated the Phase I clinical trial of sulfatinib (HMPL-012) in the United States.

6 Nov 2015

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

"This 'rotation model', which made the cover of BioEssays, represents a true paradigm shift in the membrane receptor field," stated Prof. Pierre De Meyts, a renowned researcher of insulin and receptor binding for almost half a century and one of the reviewers of the paper by Prof. Ichiro Maruyama, the head of the Information Processing Biology Unit at Okinawa Institute of Science and Technology Graduate University.

31 Oct 2015

First computational method based on evolutionary principles developed to predict protein dynamics

Researchers from the Structural Biology Computational Group of the Spanish National Cancer Research Centre, led by Alfonso Valencia, in collaboration with a group headed by Francesco Gervasio at the University College London (UK), have developed the first computational method based on evolutionary principles to predict protein dynamics, which explains the changes in the shape or dimensional structure that they experience in order to interact with other compounds or speed up chemical reactions.

26 Oct 2015

CML arterial adverse events rate dependent on TKI choice

The risk of major arterial adverse events in chronic myeloid leukaemia patients may significantly differ between tyrosine kinase inhibitors, suggests a meta-analysis published in Leukemia & Lymphoma.

22 Oct 2015

CV risk assessment essential for CML TKI trial design

The risk and impact of cardiovascular adverse events in long-term users of tyrosine kinase inhibitors for chronic myeloid leukaemia is highlighted in a review published in the Journal of Clinical Oncology.

22 Oct 2015

‘Dismal prognosis’ of blast-phase CML patients highlighted

A team of Mexican researchers reports on the poor outcomes of a large series of Mexican patients with chronic myeloid leukaemia in blast phase.

22 Oct 2015

Controlling TH-containing neurons can manipulate maternal behavior of females and aggression of males

Most female mammals give birth and care for their offspring, while the males often breed with multiple partners and play little role in parenting once the mating is over. Yet researchers have had a hard time pinpointing where, exactly, in the brain these differences between the sexes are located and how they translate into behavior. The extent of "hardwired parental behavior" is hotly disputed.

8 Oct 2015

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

6 Oct 2015

Chromosome 3q26.2 rearrangements linked to poor CML prognosis

Rearrangements of chromosome 3q26.2 have a significant negative impact on patients with chronic myeloid leukaemia, suggests research published in Blood.

1 Oct 2015

Beta-catenin shows treatment target potential for TKI-resistant CML

Nuclear β-catenin could be a treatment target for patients whose chronic myeloid leukaemia is resistant to tyrosine kinase inhibitors independent of additional BCR–BL1 mutations, US researchers suggest.

1 Oct 2015

New drug works better than current treatments for advanced kidney cancer

A new drug has been found superior to current treatments in slowing the growth of advanced kidney cancer in patients who became resistant to the first-line therapies that had kept it in check, according to results from a clinical trial led by Dana-Farber Cancer Institute.

29 Sep 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour tissue as a sample. The test identifies 42 mutations in the epidermal growth factor receptor (EGFR) gene, the most of any In-vitro Diagnostic (IVD) on the market, and can also be used as an aid in selecting eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI).

From Roche Sequencing and Life Science 28 Sep 2015

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Kolltan Pharmaceuticals, Inc. today announced the presentation of data from a preclinical study evaluating KTN0158 in dogs with spontaneous mast cell tumors. KTN0158 is a proprietary, humanized anti-KIT IgG1 monoclonal antibody drug candidate being developed as a potential therapy for cancer and mast cell-related diseases.

28 Sep 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases - enzymes that function as an "on" or "off" switch in many cellular processes, including cancer.

26 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

Tyrosine News and Research

Comorbidities relevant to CML TKI choice common

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Rare variants linked with Parkinson’s disease

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Sorafenib increases progression-free survival and disease control rate in NSCLC patients

Hutchison MediPharma begins sulfatinib Phase I trial in US

Rotation model provides explanation of ligand activation mechanism of dimeric receptors

First computational method based on evolutionary principles developed to predict protein dynamics

CML arterial adverse events rate dependent on TKI choice

CV risk assessment essential for CML TKI trial design

‘Dismal prognosis’ of blast-phase CML patients highlighted

Controlling TH-containing neurons can manipulate maternal behavior of females and aggression of males

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Chromosome 3q26.2 rearrangements linked to poor CML prognosis

Beta-catenin shows treatment target potential for TKI-resistant CML

New drug works better than current treatments for advanced kidney cancer

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Kolltan announces presentation of data from KTN0158 preclinical study in mast cell tumors at ESMO 2015

Patients with advanced kidney cancer benefit from cabozantinib treatment

BGB324 shows enhanced tumour clearance in mouse carcinoma models

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News